2011
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2011, 107: ajg2011443. PMID: 22186979, PMCID: PMC3321505, DOI: 10.1038/ajg.2011.443.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsChi-Square DistributionDouble-Blind MethodDrug CombinationsDuodenal UlcerEndoscopy, GastrointestinalFamotidineFemaleHumansIbuprofenMaleMiddle AgedProportional Hazards ModelsRisk FactorsStomach UlcerTreatment OutcomeConceptsPrimary end point analysisNon-steroidal anti-inflammatory drugsUpper GI ulcersDuodenal ulcerGI ulcersGastric ulcerEnd-point analysisDaily non-steroidal anti-inflammatory drugsH. pylori stool testDouble-blind randomized trialsMultiple potential risk factorsReduction of gastricSingle-tablet combinationUpper gastrointestinal ulcersDouble-blind trialProportional hazards analysisPotential risk factorsAnti-inflammatory drugsBaseline endoscopyREDUCE studyStudy endoscopyTablets thriceUlcer complicationsStool testRandomized trials
2008
Gastric Mucosal Defense and Cytoprotection: Bench to Bedside
Laine L, Takeuchi K, Tarnawski A. Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. Gastroenterology 2008, 135: 41-60. PMID: 18549814, DOI: 10.1053/j.gastro.2008.05.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsStress-related mucosal diseaseProton pump inhibitorsMucosal defenseGastric mucosal defenseMucosal injuryNoxious factorsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsGeneration of PGsImportant clinical sequelaeUpper gastrointestinal complicationsHigh-risk patientsModern intensive careAbsolute risk reductionInhibition of cyclooxygenaseAnti-inflammatory drugsContinuous blood flowGastrointestinal complicationsClinical sequelaePharmacologic therapyAntisecretory drugsSignificant bleedingAnnual incidenceIntensive careSensory innervationIntragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Laine L, Shah A, Bemanian S. Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers. Gastroenterology 2008, 134: 1836-1841. PMID: 18423628, DOI: 10.1053/j.gastro.2008.03.006.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralDrug Administration ScheduleDuodenal UlcerDuodenoscopyFemaleGastric AcidGastric Acidity DeterminationGastroscopyHumansHydrogen-Ion ConcentrationInfusions, IntravenousMaleMiddle AgedPeptic Ulcer HemorrhageProton Pump InhibitorsStomach UlcerTime FactorsTreatment OutcomeConceptsProton pump inhibitor therapyOral PPIIntravenous PPIInhibitor therapyConfidence intervalsStudy periodFrequent oral dosingHigh-risk stigmataSimilar antisecretory effectIntravenous lansoprazoleOral lansoprazolePPI therapyAntisecretory effectWide confidence intervalsIntragastric pHIntravenous bolusBleeding ulcersOral dosingPatientsBaseline pHUlcersAbstractTextTherapyAIMSBolus
2004
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004, 127: 395-402. PMID: 15300570, DOI: 10.1053/j.gastro.2004.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDrug Therapy, CombinationFemaleGastric MucosaHumansIbuprofenIncidenceIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesRisk FactorsStomach UlcerSulfonesTablets, Enteric-CoatedConceptsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinCOX-2 selective inhibitorsDouble-blind trialUlcer incidenceNonselective NSAIDsLow-dose enteric-coated aspirinLow-dose aspirin usersCyclooxygenase-2 selective inhibitorSelective inhibitorNonsteroidal anti-inflammatory drugsEnteric-coated aspirinGastrointestinal mucosal injuryNumber of erosionsRisk of ulcerAnti-inflammatory drugsCOX-2 selective inhibitionYears of ageBaseline endoscopyAspirin usersDose aspirinErosive esophagitisCumulative incidenceMucosal injuryRepeat endoscopyProton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Gastroenterological Disorders 2004, 4 Suppl 4: s33-41. PMID: 15580145.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI symptomsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinAnti-inflammatory drugsGI symptomsGI complicationsGI riskSide effectsDevelopment of NSAIDDaily proton pump inhibitor therapyHistamine-2 receptor antagonistsNSAID-induced gastric ulcersProton pump inhibitor therapyNSAID-induced ulcersGI side effectsUpper GI bleedingAnti-pyretic effectsGastrointestinal toxicityGI bleedingNSAID usersUlcer complicationsCardiovascular prophylaxisInhibitor therapyStandard doses
2000
Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors
Laine, Ahnen, Mcclain, Solcia, Walsh. Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 2000, 14: 651-668. PMID: 10848649, DOI: 10.1046/j.1365-2036.2000.00768.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitor useProton pump inhibitorsLong-term acid suppressionGastric acid suppressionAcid suppressionPump inhibitorsInhibitor useBacterial overgrowthEnteric infectionsGastric adenocarcinomaHigh-dose proton pump inhibitorsCarcinoid formationLong-term proton pump inhibitor useEnterochromaffin-like cell hyperplasiaAdverse effectsChronic acid suppressionImportant clinical sequelaeLong-term protonGastrointestinal adverse effectsMalabsorption of fatVitamin B12 levelsCommon clinical problemH. pylori infectionVitamin B12 concentrationsGastric bacterial overgrowth
1999
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J, Group F. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117: 776-783. PMID: 10500058, DOI: 10.1016/s0016-5085(99)70334-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDuodenal UlcerFemaleGastric MucosaGastroscopyHumansIbuprofenIntestinal MucosaIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesStomach UlcerSulfonesConceptsUlcer ratesGastroduodenal ulcersCOX-2 specific inhibitionSymptoms of osteoarthritisNonspecific COX inhibitorNormal gastrointestinal tractTreatment of patientsBaseline endoscopyGastroduodenal ulcerationPlacebo groupCumulative incidenceOsteoarthritis patientsGastroduodenal mucosaWeek 12COX inhibitorsMucosal integrityCOX-2Gastrointestinal tractInflammatory sitesProstaglandin productionDoses 2AbstractTextEffective doseUlcersPatients
1996
Nonsteroidal Anti-Inflammatory Drug Gastropathy
Laine L. Nonsteroidal Anti-Inflammatory Drug Gastropathy. Gastrointestinal Endoscopy Clinics Of North America 1996, 6: 489-504. PMID: 8803564, DOI: 10.1016/s1052-5157(18)30351-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalGastric MucosaGastritisHumansIncidencePrognosisRisk FactorsStomach UlcerConceptsGastrointestinal complicationsSubepithelial hemorrhageNonsteroidal anti-inflammatory drug gastropathyDevelopment of NSAIDUpper abdominal symptomsGastric outlet obstructionHalf of patientsPost-treatment biopsiesH. pylori infectionReactive gastritisAbdominal symptomsMajor bleedingMinor bleedingNSAID useUlcer complicationsGastrointestinal bleedingNSAID ingestionNSAID gastropathyOutlet obstructionDuodenal ulcerGastric erosionsHistologic gastritisGastric lesionsGastric ulcerPeptic ulcerHelicobacter pylori and Complicated Ulcer Disease
Laine L. Helicobacter pylori and Complicated Ulcer Disease. The American Journal Of Medicine 1996, 100: 52s-59s. PMID: 8644783, DOI: 10.1016/s0002-9343(96)80229-4.Peer-Reviewed Original ResearchConceptsMaintenance antisecretory therapyComplicated ulcer diseaseUlcer diseaseAntisecretory therapyEradication therapyHelicobacter pyloriH. pylori eradication therapyH. pylori infection statusPylori eradication therapyMajority of patientsPeptic ulcer diseaseEnd of therapyPylori infection statusPrevalence of infectionComplicated ulcersUncomplicated ulcersRecurrent bleedingUlcer healingPatientsTherapyInfection statusUlcersDiseaseBleedingOne-thirdA prospective outcome study of patients with clot in an ulcer and the effect of irrigation
Laine L, Stein C, Sharma V. A prospective outcome study of patients with clot in an ulcer and the effect of irrigation. Gastrointestinal Endoscopy 1996, 43: 107-110. PMID: 8635701, DOI: 10.1016/s0016-5107(06)80109-4.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingEndoscopic therapyVisible vesselActive bleedingFurther bleedingGastrointestinal bleedingHemostatic therapyAdherent clotHigh-risk stigmataLow-risk findingsProspective outcome studyObservation of patientsInitial endoscopyEndoscopic findingsProspective studyExcellent outcomesUlcer baseBleedingClean baseOutcome studiesVigorous irrigationPatientsAppropriate managementVariable prevalenceTherapy
1995
A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production
Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointestinal Endoscopy 1995, 42: 428-433. PMID: 8566633, DOI: 10.1016/s0016-5107(95)70045-5.Peer-Reviewed Original ResearchConceptsProstaglandin productionWeek 1Gastrointestinal injuryGastric injuryHealthy volunteersDimension of ulcersMucosal prostaglandin productionDouble-blind trialDouble-blind comparisonWeeks of treatmentMean numberProstaglandin E2 productionAnti-ulcer drugsGastroduodenal injuryGastrointestinal symptomsUlcer complicationsPrior endoscopyStandard NSAIDsGastric erosionsGastric ulcerMucosal defectsUlcer scoreWeek 4E2 productionPlaceboInteraction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial
LAINE L, COMINELLI F, SLOANE R, CASINI‐RAGGI V, MARIN‐SORENSEN M, WEINSTEIN WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial. Alimentary Pharmacology & Therapeutics 1995, 9: 127-135. PMID: 7605852, DOI: 10.1111/j.1365-2036.1995.tb00361.x.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsH. pylori infectionNSAID ingestionProstaglandin E2 productionHistological injuryWeek 1H. pyloriGastroduodenal injuryPylori infectionNegative subjectsE2 productionWeek 4Prostaglandin productionH. pylori-associated gastritisDouble-blind trialNormal baseline endoscopyAnti-inflammatory drugsBaseline endoscopyChemical gastritisGastroduodenal damagePlacebo b.Gastrointestinal injuryNSAID useGastric histologyNSAID group
1993
HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA
Laine L. HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA. Gastroenterology Clinics Of North America 1993, 22: 117-125. PMID: 8449561, DOI: 10.1016/s0889-8553(21)00267-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsH. pylori prevalenceGastric ulcerHistologic gastritisH. pyloriGastric injuryPylori prevalenceDuodenal ulcerGastric mucosaNoxious agentsInflammatory cell infiltrateH. pylori infectionNSAID usersCell infiltratePylori infectionDuodenal contentsNSAIDsUlcersGross injuryGastritisPatientsHelicobacter pyloriPyloriInjuryMucosaPrevalence